AbbVie turns a corner; patent cliff fears were overblown

AbbVie NYSE: ABBV is turning an important corner in 2024 and is on track to resume growth. Its Humira-related patent cliff aside, the business is stronger than ever, and the patent cliff is more of a bump than a steep drop. The takeaway for investors is that Humira sales are resilient, doctors and…#abbv #humira #nonhumira #rinvoq #ubrelvy #abbvie #q4 #immunology #oncology #botox
Source: Reuters: Health - Category: Consumer Health News Source Type: news